Aptorum Group announces addition of Dr Laura A Philips to board as part of merger with DiamiR Biosciences update

Reuters

2025/10/09

Aptorum Group announces addition of Dr Laura A Philips to board as part of merger with DiamiR Biosciences update

Aptorum Group Limited is moving forward with its planned merger with DiamiR Biosciences Corp., expecting to close the transaction in the fourth quarter of 2025 following stockholder approval and customary closing conditions. As part of the agreement, DiamiR will become a wholly-owned subsidiary of Aptorum Group. The combined company will see an expanded board, with Dr. Laura A. Philips joining as an independent director at closing, Dr. Kira Sheinerman, DiamiR's co-founder and director, joining the board, and Dr. Alidad Mireskandari, DiamiR's CEO, taking an observer seat on the board and serving as President and Chief Operating Officer of the merged entity. The companies anticipate that the merger will strengthen their capabilities and presence in the development and commercialization of minimally invasive tests for early detection and monitoring of brain diseases.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aptorum Group Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9543006-en) on October 09, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2574083157"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2574083157\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2574083157?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-09 20:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2574083157","market":"fut","top_or_hot":-1,"title":"Aptorum Group announces addition of Dr Laura A Philips to board as part of merger with DiamiR Biosciences update","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Aptorum Group announces addition of Dr Laura A Philips to board as part of merger with DiamiR Biosciences update\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Aptorum Group Limited is moving forward with its planned merger with DiamiR Biosciences Corp., expecting to close the transaction in the fourth quarter of 2025 following stockholder approval and customary closing conditions. As part of the agreement, DiamiR will become a wholly-owned subsidiary of Aptorum Group. The combined company will see an expanded board, with Dr. Laura A. Philips joining as an independent director at closing, Dr. Kira Sheinerman, DiamiR's co-founder and director, joining the board, and Dr. Alidad Mireskandari, DiamiR's CEO, taking an observer seat on the board and serving as President and Chief Operating Officer of the merged entity. The companies anticipate that the merger will strengthen their capabilities and presence in the development and commercialization of minimally invasive tests for early detection and monitoring of brain diseases.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aptorum Group Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9543006-en) on October 09, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aptorum Group announces addition of Dr Laura A Philips to board as part of merger with DiamiR Biosciences update</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAptorum Group announces addition of Dr Laura A Philips to board as part of merger with DiamiR Biosciences update\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-09 20:55</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Aptorum Group announces addition of Dr Laura A Philips to board as part of merger with DiamiR Biosciences update\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Aptorum Group Limited is moving forward with its planned merger with DiamiR Biosciences Corp., expecting to close the transaction in the fourth quarter of 2025 following stockholder approval and customary closing conditions. As part of the agreement, DiamiR will become a wholly-owned subsidiary of Aptorum Group. The combined company will see an expanded board, with Dr. Laura A. Philips joining as an independent director at closing, Dr. Kira Sheinerman, DiamiR's co-founder and director, joining the board, and Dr. Alidad Mireskandari, DiamiR's CEO, taking an observer seat on the board and serving as President and Chief Operating Officer of the merged entity. The companies anticipate that the merger will strengthen their capabilities and presence in the development and commercialization of minimally invasive tests for early detection and monitoring of brain diseases.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aptorum Group Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9543006-en) on October 09, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251009:nNDL7GrYwS:1","article_id":"2574083157","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2574083157","pubTimestamp":1760014528,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Aptorum Group Limited is moving forward with its planned merger with DiamiR Biosciences Corp., expecting to close the transaction in the fourth quarter of 2025 following stockholder approval and customary closing conditions. As part of the agreement, DiamiR will become a wholly-owned subsidiary of Aptorum Group. The combined company will see an expanded board, with Dr. Laura A. Philips joining as an independent director at closing, Dr. Kira Sheinerman, DiamiR's co-founder and director, joining the board, and Dr. Alidad Mireskandari, DiamiR's CEO, taking an observer seat on the board and serving as President and Chief Operating Officer of the merged entity. The companies anticipate that the merger will strengthen their capabilities and presence in the development and commercialization of minimally invasive tests for early detection and monitoring of brain diseases.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","BK4112":"金融交易所和数据","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","APM":"知临集团","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4139":"生物科技","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","BK4588":"碎股","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","NDAQ":"纳斯达克OMX交易所"},"translate_title":"Aptorum Group宣布Laura A Philips博士加入董事会，作为与DiamiR Biosciences合并的一部分更新","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"APM":0.9},"content_text":"Aptorum Group announces addition of Dr Laura A Philips to board as part of merger with DiamiR Biosciences update\n    \n\n        Aptorum Group Limited is moving forward with its planned merger with DiamiR Biosciences Corp., expecting to close the transaction in the fourth quarter of 2025 following stockholder approval and customary closing conditions. As part of the agreement, DiamiR will become a wholly-owned subsidiary of Aptorum Group. The combined company will see an expanded board, with Dr. Laura A. Philips joining as an independent director at closing, Dr. Kira Sheinerman, DiamiR's co-founder and director, joining the board, and Dr. Alidad Mireskandari, DiamiR's CEO, taking an observer seat on the board and serving as President and Chief Operating Officer of the merged entity. The companies anticipate that the merger will strengthen their capabilities and presence in the development and commercialization of minimally invasive tests for early detection and monitoring of brain diseases.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aptorum Group Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9543006-en) on October 09, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"executive,merge","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}